Initial clinical data, with a focus on assessments of safety and enzyme activity, from the first cohort of the GALILEO-1 Phase 1/2 trial of FLT201 is expected in the third quarter of 2023. GALILEO-1 is a first-in-human, international, multicenter Phase 1/2 dose-finding study assessing the safety, tolerability, and efficacy of a single intravenous dose of FLT201, the company’s adeno-associated virus gene therapy candidate for Gaucher disease Type 1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FRLN:
- Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
- Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
- Freeline to hold a virtual event
- Freeline to Participate in Upcoming Investor Conferences
- Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
